|
|
|
|
|
Legal status
Patent not validated
| (51) | INT.CL. | A61K 31/53 | |
| A61K 31/7068 | |||
| A61P 35/00 | |||
| A61P 35/02 | |||
| A61K 45/06 | |||
| A61K 9/00 |
| (11) | Number of the document | 3362070 |
| (13) | Kind of document | T |
| (96) | European patent application number | 16788866.8 |
| Date of filing the European patent application | 2016-10-14 | |
| (97) | Date of publication of the European application | 2018-08-22 |
| (45) | Date of publication and mention of the grant of the patent | 2021-01-27 |
| (46) | Date of publication of the claims translation |
| (86) | Number | PCT/US2016/057102 |
| Date | 2016-10-14 |
| (87) | Number | WO 2017/066611 |
| Date | 2017-04-20 |
| (30) | Number | Date | Country code |
| 201562242218 P | 2015-10-15 | US |
| (72) |
CHOPRA, Vivek, Saroj, Kumar, US
DIMARTINO,Jorge, US
KENVIN, Laurie, A., US
KNIGHT, Robert, Douglas, US
MACBETH, Kyle, US
VISWANADHAN, Krishnan, US
XU, Qiang, US
AGRESTA, Samuel, V., US
|
| (73) |
Celgene Corporation,
86 Morris Avenue, Summit, NJ 07901,
US
Agios Pharmaceuticals, Inc., 88 Sidney Street, Cambridge, MA 02139, US |
| (54) | COMBINATION OF A MUTANT ISOCITRATE DEHYDROGENASE 2 INHIBITOR WITH AZACITIDINE AND ITS USE FOR TREATING ACUTE MYELOGENOUS LEUKEMIA |
| COMBINATION OF A MUTANT ISOCITRATE DEHYDROGENASE 2 INHIBITOR WITH AZACITIDINE AND ITS USE FOR TREATING ACUTE MYELOGENOUS LEUKEMIA |